The objective of the research was to study the frequency of remission in young adults with juvenile idiopathic arthritis during the transition period from paediatric to adult healthcare and factors contributing to its development. Materials and methods.
Problem statement and analysis of the recent research
The clinical course of juvenile idiopathic (rheumatoid) arthritis (JIA) [1] in adulthood and at the stage of transition from paediatric to adult healthcare, as well as the frequency of remission have not been sufficiently studied yet [2, 4] . The clinical course of JIA in childhood is known to be both monocyclic and polycyclic and may be characterized by long-term remissions [3, 7] . However, the clinical course of JIA in adulthood and the features of the development and diagnosis of remission in adult patients have been insufficiently studied.
According to the International League of Associations for Rheumatology (ILAR) prognosis, patients with oligoarticular JIA go into remission most frequently. Adult rheumatologists are not always aware of this JIA subtype, as the clinical course of rheumatoid disease has no equals in adulthood. Oligoarticular JIA is characterized by the presence of positive antinuclear antibodies (ANA). It occurs most often in girls at the age of 2-6 years with the development of arthritis involving less than 4 joints. This variant is characterized by the favourable prognosis and long-term remissions. In other JIA variants, remission occurs more rarely. Although, a significant proportion of young adults with JIA present persistent disease activity, no unified approaches to its measurement have been developed yet [5, 6, 7, 11] . The Juvenile Arthritis Disease Activity Score (JADAS) [12] is known to be used for assessing disease activity in childhood. It has different variations depending on the number and location of the joints considered while calculating the score: JADAS-71, JADAS-27, JADAS-10 or cJADAS (JADAS-3). This scale allows determining disease activity in JIA by estimation of the sum of the following parameters: the physician's global assessment of disease activity (measured on a 0-10 visual analog scale (VAS)); the patient's/parent's global assessment of wellbeing (measured on a 0-10 VAS); the assessment of 71, 27 or 10 involved joints, joint count (71, 27, 10), active joint count (JADAS-71, JADAS-27 and JADAS-10, respectively); normalized C-reactive protein (C-RP) or erythrocyte sedimentation rate (ESR) measured by the Westergren method. Recently, in paediatric practice, the JADAS-3 which excludes the determination of the ESR or C-RP has been used. It is calculated using the three aforementioned clinical indicators. According to the JADAS-10, disease activity in childhood is assessed as follows: for oligoarthritis and polyarthritis, the disease is considered inactive at the JADAS-10<1; oligoarthritis activity is low at the JADAS-10<2, polyarthritis activity is low at the JADAS-10<3.8; oligoarthritis activity is moderate at the JADAS-10 of 2.1-4.2, polyarthritis activity is moderate at the JADAS-10 of 3.9-10.5; oligoarthritis activity is considered to be high at the JADAS-10>4.2, polyarthritis activity is considered to be high at the JADAS-10>10.5 [12] . In 2006, A. Ravelli, and A. Martini proposed to differentiate between "inactive disease" and "clinical remission" [10] . JIA is considered inactive when there are no joints with active arthritis, no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, no active uveitis; normal ESR or C-RP; physician's global assessment of disease activity indicates no disease activity.
For the concept of "achieving clinical remission" two options were proposed:
1. Clinical remission with medication. The criteria for inactive disease must be met for a minimum of 6 consecutive months while the patient is taking medication 2. Clinical remission without medication. The criteria for inactive disease must be met for a minimum of 12 consecutive months while the patient is not taking any anti-arthritis and anti-uveitis medications. There are certain criteria for determining the absence of disease activity, namely the absence of the joints with active arthritis, fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, uveitis; normal ESR or CRP or the absence of association of their increase with JIA, duration of morning stiffness <15 min.
However, remission in JIA is a controversial issue being insufficiently studied [9, 11] . There is no consensus method of assessing JIA activity and remission in adulthood, and the factors associated with remission development have not been sufficiently study as well. The objective of the research was to study the frequency of remission in young adult patients during the transition period from paediatric to adult healthcare and in adulthood as well as factors contributing to its development.
Materials and methods
The study included 165 adult patients with JIA who were transferred to adult rheumatology services. This group included patients residing in different regions of Ukraine who were diagnosed with JIA during 1984-2013. Inclusion criteria were as follows: patients with JIA according to the ILAR criteria [8] ; patients over 18 years of age without severe comorbidity whose diagnosis of JIA was reviewed retrospectively. Patients with disease duration of less than 3 years were excluded from the study. There was conducted a retrospective analysis of the patients' medical records including the patient's age at disease onset, the time elapsed between the first clinical manifestations and the time of diagnosis, disease activity at disease onset and treatment received in childhood. All the patients over 18 years of age were examined as outpatients or inpatients in the Oleksandrivska City Clinical Hospital, Kyiv from April 2015 to Mai 2018. There were assessed disease duration, the ILAR variant at disease onset, the presence of rheumatoid factor (RF), anti-cyclic citrullinated peptide (A-CCP), ANA, human leukocyte antigen B27 (HLA-B27), disease activity according to the JADAS-10 and the Disease Activity Score-28 (DAS-28), C-RP, treatment received by the patient at the time of examination and past medical history including immunobiological therapy (IBT). Quality of life (QoL) in patients with JIA was evaluated using the 36-Item Short Form Health Survey (SF-36). The degree of depression was assessed using the Patient Health Questionnaire-9 (the PHQ-9) and the degree of alexithymia was assessed using the 20-item Toronto Alexithymia Scale (TAS-20). In all the patients, bone mineral density (BMD) was studied using dualenergy x-ray absorptiometry with the evaluation of T-and Z-scores in different regions of the skeleton.
The presence of active disease and remission in adulthood was assessed. The disease was considered inactive at the DAS-28 <2.6 and the JADAS-10 <1 and <2 for oligoarticular and polyarticular variants of JIA, respectively, that were assessed in patients simultaneously.
Results and discussion
All the patients were divided into 2 groups: Group I included 136 (82.4%) patients with active disease at the time of examination by an adult rheumatologist; Group II comprised 29 (17.6%) patients who achieved remission according to the DAS-28 or the JADAS-10. Table 1 presents general characteristics of young adult patients with JIA. Thus, patients who achieved remission did not differ in age while carrying out the research; however, in the group of active disease, women prevailed accounting for 58.1% of patients as compared to the group of patients who achieved remission (31.0%). Patients of both groups did not differ in height, although they had larger body weight (p<0.01) and, accordingly, higher body mass index (BMI); however, it was within the normal BMI range. Disease duration was longer in patients of Group I (p<0.01); however, they did not differ from patients of Group II in age at disease onset and the ILAR variants of JIA.
The analysis of clinical manifestations (Table 2) revealed that in patients of Group II, lesions involving more than 3 joints (p<0.01), hand arthritis (p<0.01), symmetric arthritis (p<0.01), enthesitis (p<0.01), spinal pain (p<0.01) were observed less frequently. Fewer patients required joint replacement (p<0.01); the number of deformed and painful joints (p<0.05, p<0.001, respectively) was accordingly smaller. When examining patients of Group II, there were observed no X-ray changes, or they were more often diagnosed with X-ray stage I according to the criteria proposed by Sharp (p<0.001).
Patients of both groups differed in the DAS-28, the JADAS, the physician's/patient's global health assessment (measured on a 0-10 VAS), C-RP and ESR (all p-values <0.01), that are responsible for the activity of the process (Table 3) . However, there was no difference in the levels of RF, A-CCP, ANA and the presence of HLA-B27. There were no differences in the levels of total cholesterol, low-density lipoproteins (LDL), and glucose serving as risk factors for atherosclerosis.
BMD is known to reduce more often in patients with chronic inflammatory diseases. Therefore, we studied serum levels of 25-hydroxyvitamin D (25 (OH) D), total and ionized calcium in patients of both groups; however, there were observed no statistically significant differences between the two groups. Table 4 presents the results of studying BMD in young adult patients with JIA who achieved remission and those with active disease. There were some differences in the lumbar spine (LS) by Z-score, the femoral neck (FN) by BMD and Z-score and the ultra-distal region of the forearm by BMD (all p-values<0.05).
The analysis of QoL, alexithymia and depression in young adult patients with JIA who achieved remission and those with active disease (Table 5 ) revealed significant impact of active disease. Thus, the achievement of remission improved physical well-being of patients (the physical component score (PCS), p<0.001), although overall mental well-being (the mental component score (MCS)) did not change. According to the SF-36, in patients with remission, the indicators of physical functioning (PF) (p<0.001), role functioning (RF) (p<0.001), social functioning (SF) (p<0.001), bodily pain (BP) (p<0.001), general health (GH) (p<0.001), mental health (MH) (p<0.001) improved. There was observed a reduction in the level of depression to the normal one according to the PHQ-9 (p<0.05); however, in both groups, there were observed elevated levels of alexithymia and they did not differ in this indicator.
The analysis of drug therapy in young adult patients with JIA who achieved remission and those with active disease (Table 6 ) revealed that they did not differ in the frequency of IBT prescription; however, the results should be intepreted with caution, since among patients who achieved remission, only 5 (17.1%) individuals received IBT earlier or at the time of examination. However, patients with JIA who achieved remission turned out more often not to receive glucocorticoids (GCs) at the time of examination (p<0.001) and earlier (p<0.001). Both groups did not differ in both the duration of basic therapy with disease-modifying antirheumatic drugs (DMARDS) and the doses of methotrexate and sulfasalazine.
Conclusions
Thus, according to the results of our study, remission was detected in 17.6% of the surveyed young adult patients from different regions of Ukraine during the transition period from paediatric to adult healthcare and in adulthood, that indicated that in most cases the goal of treat-to-target strategy was not achieved. Patients with active disease often developed joint deformities and required their replacement; they had worse physical well-being according to the SF-36, although mental well-being was affected in both patients with active disease and those with remission, which may be due to high levels of alexithymia in both groups. Patients with active disease had higher levels of depression according to the PHQ-9, whereas patients in remission showed no depression.
Prospects for further research
Further studies of factors contributing to the development of JIA remission in adulthood considering past IBT are essential. 
